{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:30:38Z","timestamp":1784320238064,"version":"3.55.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD004794"],"award-info":[{"award-number":["R01FD004794"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD004794"],"award-info":[{"award-number":["R01FD004794"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Pretomanid is a new nitroimidazole with proven treatment-shortening efficacy in drug-resistant tuberculosis. Pretomanid\u2013rifamycin\u2013pyrazinamide combinations are potent in mice but have not been tested clinically. Rifampicin, but not rifabutin, reduces pretomanid exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of regimens containing pretomanid\u2013rifamycin\u2013pyrazinamide among participants with drug-sensitive pulmonary tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A phase 2, 12-week, open-label randomized trial was conducted of isoniazid and pyrazinamide plus 1) pretomanid and rifampicin (arm 1), 2) pretomanid and rifabutin (arm 2), or 3) rifampicin and ethambutol (standard of care; arm 3). Laboratory values of safety and sputum cultures were collected at Weeks 1, 2, 3, 4, 6, 8, 10, and 12. Time to culture conversion on liquid medium was the primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Among 157 participants, 125 (80%) had cavitary disease. Median time to liquid culture negativity in the modified intention-to-treat population (n\u2009=\u2009150) was 42 (arm 1), 28 (arm 2), and 56 (arm 3) days (P\u2009=\u20090.01) (adjusted hazard ratio for arm 1 vs. arm 3, 1.41 [95% confidence interval (CI), 0.93\u20132.12; P\u2009=\u20090.10]; adjusted hazard ratio for arm 2 vs. arm 3, 1.89 [95% CI, 1.24\u20132.87; P\u2009=\u20090.003]). Eight-week liquid culture conversion was 79%, 89%, and 69%, respectively. Grade \u22653 adverse events occurred in 3 of 56 (5%), 5 of 53 (9%), and 2 of 56 (4%) participants. Six participants were withdrawn because of elevated transaminase concentrations (five in arm 2, one in arm 1). There were three serious adverse events (arm 2) and no deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pretomanid enhanced the microbiologic activity of regimens containing a rifamycin and pyrazinamide. Efficacy and hepatic adverse events appeared highest with the pretomanid and rifabutin-containing regimen. Whether this is due to higher pretomanid concentrations merits exploration.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 02256696).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202208-1475oc","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T14:38:25Z","timestamp":1669905505000},"page":"929-935","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":20,"title":["Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results"],"prefix":"10.1093","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-5256","authenticated-orcid":false,"given":"Kelly E.","family":"Dooley","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Hendricks","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Gupte","sequence":"additional","affiliation":[{"name":"Johns Hopkins India Private Limited, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Barnes","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Narunsky","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Whitelaw","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Smit","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa H.","family":"Ignatius","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adine","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Dorman","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"2026012204495707400_bib1","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2021"},{"key":"2026012204495707400_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012204495707400_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00849-10","article-title":"PA-824 exhibits time-dependent activity in a murine model of tuberculosis","volume":"55","author":"Ahmad","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012204495707400_bib5","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.00686-08","article-title":"Enhanced bactericidal activity of rifampin and\/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis","volume":"52","author":"Tasneen","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib6","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1128\/AAC.03332-14","article-title":"Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin","volume":"58","author":"Dooley","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib7","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","article-title":"Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"2026012204495707400_bib9","doi-asserted-by":"crossref","first-page":"e01196-20","DOI":"10.1128\/AAC.01196-20","article-title":"Pretomanid pharmacokinetics in the presence of rifamycins: interim results from a randomized trial among patients with tuberculosis","volume":"65","author":"Ignatius","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib10","doi-asserted-by":"crossref","first-page":"113885","DOI":"10.1016\/j.jpba.2020.113885","article-title":"A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients","volume":"195","author":"Malo","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"2026012204495707400_bib11","author":"Dooley"},{"key":"2026012204495707400_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5588\/ijtld.20.0513","article-title":"A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB","volume":"25","author":"Tweed","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012204495707400_bib13","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2026012204495707400_bib14","doi-asserted-by":"crossref","first-page":"e0231021","DOI":"10.1128\/aac.02310-21","article-title":"Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments","volume":"66","author":"Dide-Agossou","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib15","doi-asserted-by":"crossref","first-page":"e0239821","DOI":"10.1128\/aac.02398-21","article-title":"Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and\/or OPC-167832 in murine tuberculosis models","volume":"66","author":"Tasneen","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012204495707400_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13063-022-06331-8","article-title":"TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/207\/7\/929\/66438498\/ajrccm_207_7_929.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/207\/7\/929\/66438498\/ajrccm_207_7_929.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:50:04Z","timestamp":1769075404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/207\/7\/929\/8428310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4,1]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202208-1475oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"2022-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}